Cargando…
Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177786/ https://www.ncbi.nlm.nih.gov/pubmed/33728716 http://dx.doi.org/10.1111/cas.14884 |
_version_ | 1783703449431441408 |
---|---|
author | Okabe, Atsushi Kaneda, Atsushi |
author_facet | Okabe, Atsushi Kaneda, Atsushi |
author_sort | Okabe, Atsushi |
collection | PubMed |
description | Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identity and promote the development of diseases such as cancer. Tumor cells acquire aberrantly activated enhancers at oncogenic driver genes through various mechanisms. Small genomic changes such as mutations, insertions, and amplifications can form aberrant enhancers. Genomic rearrangements at the chromosomal level, including translocations and inversions, are also often observed in cancers. These rearrangements can result in repositioning of enhancers to locations near tumor‐type‐specific oncogenes. Chromatin structural changes caused by genomic or epigenomic changes lead to mis‐interaction between enhancers and proto‐oncogenes, ultimately contributing to tumorigenesis through activation of oncogenic signals. Additional epigenomic mechanisms can also cause aberrant enhancer activation, including those associated with overexpression of oncogenic transcription factors and the mutation of transcriptional cofactors. Exogenous viral DNA can also lead to enhancer aberrations. Here, we review the mechanisms underlying aberrant oncogene activation through enhancer activation and rewiring, both of which are caused by genomic or epigenomic alterations in non‐coding regions. |
format | Online Article Text |
id | pubmed-8177786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81777862021-06-15 Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer Okabe, Atsushi Kaneda, Atsushi Cancer Sci Review Articles Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identity and promote the development of diseases such as cancer. Tumor cells acquire aberrantly activated enhancers at oncogenic driver genes through various mechanisms. Small genomic changes such as mutations, insertions, and amplifications can form aberrant enhancers. Genomic rearrangements at the chromosomal level, including translocations and inversions, are also often observed in cancers. These rearrangements can result in repositioning of enhancers to locations near tumor‐type‐specific oncogenes. Chromatin structural changes caused by genomic or epigenomic changes lead to mis‐interaction between enhancers and proto‐oncogenes, ultimately contributing to tumorigenesis through activation of oncogenic signals. Additional epigenomic mechanisms can also cause aberrant enhancer activation, including those associated with overexpression of oncogenic transcription factors and the mutation of transcriptional cofactors. Exogenous viral DNA can also lead to enhancer aberrations. Here, we review the mechanisms underlying aberrant oncogene activation through enhancer activation and rewiring, both of which are caused by genomic or epigenomic alterations in non‐coding regions. John Wiley and Sons Inc. 2021-05-01 2021-06 /pmc/articles/PMC8177786/ /pubmed/33728716 http://dx.doi.org/10.1111/cas.14884 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Okabe, Atsushi Kaneda, Atsushi Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title | Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title_full | Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title_fullStr | Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title_full_unstemmed | Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title_short | Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
title_sort | transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177786/ https://www.ncbi.nlm.nih.gov/pubmed/33728716 http://dx.doi.org/10.1111/cas.14884 |
work_keys_str_mv | AT okabeatsushi transcriptionaldysregulationbyaberrantenhanceractivationandrewiringincancer AT kanedaatsushi transcriptionaldysregulationbyaberrantenhanceractivationandrewiringincancer |